Nebivolol (Bystolic®) is a cardioselective beta 1 (β1)‐adrenergic receptor blocker with
endothelium‐dependent vasodilating properties. The endothelium‐dependent relaxation …

Nebivolol is a highly selective β 1-adrenoceptor blocker, which also stimulates endothelial
nitric oxide synthase and scavenges reactive oxygen species (ROS). These characteristics …

Nebivolol is a novel beta1-blocker with a greater degree of selectivity for beta1-adrenergic
receptors than other agents in this class and a nitric oxide (NO)-potentiating, vasodilatory …

Nebivolol is a third-generation β-adrenergic receptor antagonist (β-blocker) with high
selectivity for β 1-adrenergic receptors. In addition, it causes vasodilatation via interaction …

β-blockers are among the most widely used drugs in the prevention and treatment of
cardiovascular disease, although they are associated with increased peripheral resistance …

Nebivolol is a new and selective β 1‐adrenergic receptor antagonist whose haemodynamic
profile is different from that of classical β‐blockers. The blood pressure lowering effects of …

Although its clinical use in Europe dates almost 10 years, nebivolol is a β-blocker that has
been only recently introduced in the US market. Like carvedilol, nebivolol belongs to the …

Abstract β-adrenergic blocking agents, a pharmacologically diverse class of cardiovascular
medications, are recommended as first-line treatment for patients with hypertension and …

Nebivolol is a vasodilating β-blocker, which can be distinguished from other β-blockers by its
haemodynamic profile. It combines β-adrenergic blocking activity with a vasodilating effect …

New evidence from recently completed clinical studies performed with nebivolol, a highly
selective beta‐1 β‐blocker, endowed with additional vasodilating activity mediated by nitric …